Direct evidence of high DNA binding activity of transcription factor AP‐1 in rheumatoid arthritis synovium

Abstract

Objective. To investigate the possible activation of transcription factor AP‐1 in rheumatoid arthritis (RA) and its involvement in the pathogenesis of RA. Methods. Synovial tissues and peripheral blood samples were obtained from 25 patients with RA and 5 patients with osteoarthritis (OA) during arthroplasty and synovectomy. The synovial tissue was digested with collagenase and separated into adherent and nonadherent cells by plastic‐adhesion methods. Nuclear extracts obtained from each sample were examined by electrophoretic mobility shift assay to determine the DNA binding activity of AP‐1. The expression of c‐fos and c‐jun messenger RNA (mRNA) was examined by in situ reverse transcription assay. Results. A markedly high DNA binding activity of AP‐1 was detected in the synovial tissues of RA patients, while virtually no activity or only a little activity was observed in OA patients. Following separation of adherent and nonadherent cells, the AP‐1 activity was mainly detected in adherent cells, which consisted of synovial cells and macrophages. However, the activity was significantly higher in the mononuclear cells infiltrating into RA synovium than in RA peripheral blood mononuclear cells. The high DNA binding activity of AP‐1 in RA correlated with the expression of c‐fos and c‐jun mRNA in situ. Furthermore, AP‐1 binding activity also correlated with disease activity. Conclusion. In RA synovium, AP‐1 DNA binding activity was constitutively up‐regulated. These findings suggest that AP‐1 may play an important role in the pathogenesis of RA, including synovial hyperplasia and abnormal immune responses.

Quantitation of glucocorticoid receptor alpha and NF-κB pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients

“…It is surprising that only c-Fos did not correlate with other genes, since its pattern is supposed to be similar to that of NF-κB and IKK (Trabandt et al, 1992;Asahara et al, 1997;Shiozawa et al, 1997;Firestein, 2004;Onda et al, 2004). It is possible that some DMARDs showed a greater influence on the regulation of c-Fos than of other genes.…”

Ameliorative effects of follistatin‐related protein/TSC‐36/FSTL1 on joint inflammation in a mouse model of arthritis

“…Their expression has been associated with a proliferative role in many tissues (21,33). It has been reported that c-fos and ets-2 expression was higher in rheumatoid synovial tissue than that in normal synovial tissue, suggesting that they may play an important role in the progression of RA (22,34,35). The nuclear oncogene c-fos and its product c-Fos bind to activator protein 1 666 KAWABATA ET AL sites on matrix-degrading genes, such as MMP3 and MMP9.…”

IL-6 and Matrix Metalloproteinase-1 Are Regulated by the Cyclin-Dependent Kinase Inhibitor p21 in Synovial Fibroblasts

“…Thus, JNK activation of AP-1 may be essential for promoting proinflammatory molecule production. Furthermore, cFos and c-Jun expression correlates with synovial hyperplasia in RA synovial tissue (62), and increased AP-1 DNA-binding activity is observed in RA compared with OA synovial tissue (63,64). Addition of AP-1 oligonucleotides ameliorates joint destruction in experimental arthritis models (42).…”